SGLT-1 inhibitors are still in the research phase however a dual SGLT-1/2 inhibitor, sotagliflozin, which inhibits both SGLT-1 and SGLT-2 has shown efficacy in controlling blood glucose levels and represents a promising treatment for both T1DM and T2DM [52, 53]. This evidence concerns the gene SLC5A1 and type 1 diabetes mellitus.